<?xml version="1.0" encoding="utf-8"?>
    <rss version="2.0">
      <channel xmlns:content="http://purl.org/rss/1.0/modules/content/">
        <title>Transplant International | New and Recent Articles</title>
        <link>https://www.frontierspartnerships.org/journals/transplant-international</link>
        <description>RSS Feed for Transplant International | New and Recent Articles</description>
        <language>en-us</language>
        <generator>Frontiers Feed Generator,version:1</generator>
        <pubDate>2026-09-08T15:43:02.852+00:00</pubDate>
        <ttl>60</ttl>
        <item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16849</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16849</link>
        <title><![CDATA[Post-transplant acute pancreatitis after pancreas transplantation: application of the International Study Group for Pancreatic Surgery definition and clinical impact in a multicenter cohort study]]></title>
        <pubdate>2026-09-08T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Stefano Partelli</author><author>Valentina Andreasi</author><author>Matteo Santangelo</author><author>Oriana Ciacio</author><author>Rossana Caldara</author><author>Arianna Bertuol</author><author>Valentina Tomajer</author><author>Davide Catarinella</author><author>Alessandra Ida</author><author>Caterina Di Bella</author><author>Gabriella Pittau</author><author>Chady Salloum</author><author>Gioia Sgrinzato</author><author>Paolo Rigotti</author><author>Lorenzo Piemonti</author><author>Antonio Sa Cunha</author><author>Lucrezia Furian</author><author>Massimo Falconi</author>
        <description><![CDATA[Graft pancreatitis is a clinically relevant but poorly standardized complication after pancreas transplantation (PT). In contrast, post-pancreatectomy acute pancreatitis has been formally defined and validated by the International Study Group for Pancreatic Surgery (ISGPS). This study assessed the clinical applicability of an adapted ISGPS-based framework to define post-transplant acute pancreatitis (PTAP) after PT and its association with clinically relevant outcomes. Consecutive patients undergoing PT at three European centers between 2010 and 2024 were included. PTAP was defined by sustained postoperative hyperamylasemia (POH) for ≥48 h combined with CT findings consistent with pancreatitis within 30 days after transplantation. Imaging was performed in 89% of patients based on clinical indication and center-specific protocols. Among 432 patients, the adapted definition was applicable in 416. Sustained POH occurred in 196 patients (47%), and PTAP was diagnosed in 86 (21%). PTAP was the only independent predictor of severe postoperative complications (OR, 2.482; P = 0.001), was independently associated with prolonged hospital stay (OR, 3.817; P < 0.001), and with worse death-censored graft survival (P < 0.001). Cold ischemia time was the only independent determinant of PTAP (P < 0.001). PTAP was a frequent and clinically meaningful complication after PT, occurring in approximately one in five patients and associated with worse short- and long-term outcomes.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16653</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16653</link>
        <title><![CDATA[The perfused liver utilisation study (PLUS): challenges and innovation in the evaluation of an emerging technology]]></title>
        <pubdate>2026-09-08T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Simon Robert Knight</author><author>Helen L. Thomas</author><author>Rosemary Brown</author><author>Charlie Brown</author><author>Kerrie Brusby</author><author>Emily Arbon</author><author>Laura Silsby</author><author>Alice Newton</author><author>Jennifer Mehew</author><author>Aleema Iqbal</author><author>Katie Keen</author><author>Syeda Bahar</author><author>Christopher Watson</author><author>Brian Davidson</author><author>David Nasralla</author><author>Carlo Ceresa</author><author>Barbara Fiore</author><author>Ahmed E. Sherif</author><author>Colin Wilson</author><author>Balaji Mahendran</author><author>Joerg-Matthias Pollok</author><author>Rebeca S. Mateos</author><author>Wayel Jassem</author><author>Rohit Gaurav</author><author>Gabriel C. Oniscu</author><author>Craig Marshall</author><author>Angus Hann</author><author>Reena Ravikumar</author><author>Constantin Coussios</author><author>Peter J. Friend</author>
        <description><![CDATA[Previous studies suggest that donor liver normothermic machine perfusion (NMP) reduces injury and enables functional assessment, resulting in an increase in utilisation. The PLUS study was designed to assess the impact of NMP availability on utilisation of livers at high risk of non-use. Using a threshold-crossing design, functional utilisation was assessed in a real-world retrospective registry-based control cohort. A predetermined efficacy threshold was set, and a prospective cohort was recruited in all UK liver transplant centres with NMP made available for all livers at high risk of non-utilisation. Availability of NMP resulted in a significant increase in functional utilisation (OR: 1.26, 95% CI: 1.04–1.53), but this did not exceed the pre-determined efficacy threshold. The threshold was exceeded in the subgroup of donation after circulatory death (DCD) livers, although this increase was reduced with adjustment for the use of normothermic regional perfusion. NMP was used in only 31% of retrieved livers, with variation between centres. The benefit of having NMP available was less than anticipated, likely due to low use in some centres associated with staff availability. Provision of NMP as a service, or centralisation of NMP use in assessment and recovery centres, may improve uptake.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16762</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16762</link>
        <title><![CDATA[Improved access to kidney transplantation with favorable graft survival in highly sensitized candidates under the French acceptable mismatch program]]></title>
        <pubdate>2026-09-08T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Corinne Antoine</author><author>Emilie Savoye</author><author>Benoit Audry</author><author>Camille Legeai</author><author>Myriam Pastural</author><author>Anne Cesbron</author><author>Valerie Dubois</author><author>Jean-Luc Taupin</author>
        <description><![CDATA[The scarcity of the human leukocyte antigen (HLA)-compatible donor pool, which leads to a long waiting time for transplantation, often requires specific national or supranational strategies to improve kidney graft access for highly sensitized (HS) patients. Acceptable national mismatch priority is a way to increase the number of potential matched donors without increasing the immunologic graft failure risk. In 2005, the French Acceptable Mismatch program (AMP) was successfully introduced as a strategy to improve kidney allocation for HS patients. The AMP was enhanced in 2015, authorizing up to four HLA-A, -B, -DR, and -DQβ mismatches, provided that each mismatch was an acceptable antigen. Our study compared graft survival between AMP allocation and other kidney allocation modalities among HS recipients between 2016 and 2022 (N = 2,985). After adjustment for donor and recipient characteristics using Cox regression, we found that the risk of graft failure was higher for HS non-AMP transplantations (hazard ratio 1.19 [95% CI 1.04–1.36]; 1.31 [95% CI 1.08–1.59] with death censored). The French AMP improves access to kidney transplantation for HS patients. Post-transplant survival is comparable to other kidney allocation modalities, possibly because of the absence of preformed donor-specific antibodies in recipients’ historical and recent serum, which is associated with reduced risk of rejection.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16970</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16970</link>
        <title><![CDATA[Sequential dual-organ living donation: selection, operative approach, and early donor outcomes at a Canadian center]]></title>
        <pubdate>2026-09-07T00:00:00Z</pubdate>
        <category>Brief Research Report</category>
        <author>Su Kah Goh</author><author>Nazia Selzner</author><author>Sunita K. Singh</author><author>Ian D. McGilvray</author><author>Chaya Shwaartz</author><author>Trevor W. Reichman</author><author>Nicolas Goldaracena</author><author>Jason Y. Lee</author><author>Markus Selzner</author><author>Gonzalo Sapisochin</author><author>Blayne Amir Sayed</author><author>Mark S. Cattral</author><author>Anand Ghanekar</author>
        <description><![CDATA[Sequential dual-organ living donation, defined as donation of a kidney and a partial liver graft by the same individual in separate operations, represents a rare extension of living donor transplantation. A donor-focused analysis was performed to characterize the donor population, the operative considerations posed by a second donor operation, and early donor outcomes at a single high-volume center. A retrospective review of all dual-organ living donors at our institute was performed. Twenty-four donors were identified (n = 10 liver-first and n = 14 kidney-first). The median interval between donations was 2 years (IQR 1.1–4.2). Twelve donors donated both organs anonymously, nine donated one organ anonymously and directed the other, and three directed both donations. Anonymous donation is a strong motivator in this unique population. Ten donors (42%) participated in kidney paired donation. Liver donations (left lateral segment (42%), left lobe (25%), and right lobe (33%)) were performed by an open approach. Laparoscopic nephrectomy was performed in all cases except two prior liver donors. Liver-after-kidney donors (n = 14) did not develop renal dysfunction after donation. Prior organ donation does not usually require modification of surgical technique for the second procedure. Dual-organ living donation is rare but can be safely performed independent of sequence.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16846</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16846</link>
        <title><![CDATA[Menopause influences lung inflammatory response and miRNA expression in brain death donors]]></title>
        <pubdate>2026-09-04T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Elizabeth Cristina Miola</author><author>Nicholas Pietro Agulha Toneto</author><author>Fernanda Yamamoto Ricardo-da-Silva</author><author>Pedro Luis Zonta de Freitas</author><author>Marina Vidal-dos-Santos</author><author>Luciana Coelho Marques</author><author>Henri Gerrit Derk Leuvenink</author><author>Luiz Felipe Pinho Moreira</author><author>Cristiano Jesus Correia</author><author>Ana Cristina Breithaupt-Faloppa</author>
        <description><![CDATA[Lungs are highly affected by brain death, with females showing a higher inflammatory response, linked sex hormones acute reduction. With the aging of world population, the number of older donors is increasing. So, the study of menopause associated changes gain importance. Here we investigated menopause’s effects in female brain death rats, previously subjected to transitional follicular depletion and aging. Female Wistar rats were divided in young and menopause groups. After follicular depletion, rats aged for 10 weeks. The animals were submitted to brain death and Sham operated rats served as controls. White blood cell counts, bronchoalveolar lavage were analyzed and inflammatory mediators were quantified. Lung tissue was evaluated for myeloperoxidase, intercellular adhesion molecules, miRNA expression, and protein and gene expression of estradiol receptors. In menopause group, there was increase in systemic and tissue leukocyte infiltration, myeloperoxidase expression, inducible nitric oxide synthase, intercellular adhesion molecule-1, lung edema, and loss of IL-10 regulation. Additionally, we found alterations in estradiol receptors along with changes in the expression of miRNAs associated to inflammation, vascular function and senescence. Menopause increases lung inflammation after brain death, by higher leukocyte infiltration and reduction of IL-10 and may impact the outcome of lung transplantation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16525</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16525</link>
        <title><![CDATA[Beyond generic principles: a framework for the ethical analysis of artificial intelligence in organ transplantation]]></title>
        <pubdate>2026-09-04T00:00:00Z</pubdate>
        <category>Point of View</category>
        <author>Nadia Primc</author>
        <description><![CDATA[Artificial intelligence (AI) is increasingly entering clinical medicine, and organ transplantation is no exception. While a growing body of literature addresses the ethical challenges of AI in healthcare, systematic analysis of the specific ethical dimensions of AI use in organ transplantation is missing. This gap reflects a genuine analytical challenge: the transplantation process is ethically complex in ways that general AI ethics frameworks do not adequately capture. Transplantation medicine simultaneously bears ethical obligations to deceased donors, living donors, donor families, organ recipients, and the public at large. These obligations shift substantially across the stages of the transplantation process, from the patient-centred ethics of donor identification and listing decisions, through the distributive justice logic governing organ allocation, to the professional responsibility questions of the peri- and post-transplant phases. A rigorous ethical analysis of AI in organ transplantation therefore requires, first, a systematic mapping of AI use cases and models onto the transplantation process; second, an identification of the stakeholder-specific ethical obligations pertinent at each stage; and third, an in-depth analysis of how those obligations are specifically affected by the properties of the AI system in question. This paper proposes this framework and illustrates it using the example of AI-assisted organ allocation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16483</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16483</link>
        <title><![CDATA[Public perception of xenotransplantation and its implication for policy and regulation: lessons learnt from a qualitative study of the Swedish public]]></title>
        <pubdate>2026-09-03T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Rui Liu</author><author>Markus Idvall</author><author>Susanne Lundin</author>
        <description><![CDATA[The field of xenotransplantation is advances rapidly. Its cross-species nature creates regulatory challenges different from those in allotransplantation. Public opinion is promoted as an essential element in developing responsible governance for this technology. This study takes a qualitative thematic approach to analyze data collected through a questionnaire (n = 136) to the Swedish public. The aim is, first, to analyze how respondents articulate concerns, hopes, and moral evaluations regarding XT, and second, to reflect on what these responses reveal about the methodological conditions required for meaningful public engagement in the development of regulatory frameworks for emerging biomedical technologies. The findings demonstrate that public views are not directly associated with the technical assessment of risk and benefit but are anchored in shifting sociocultural perceptions regarding human survival, animal welfare, and vulnerability as individuals move between different scenarios. We conclude that developing policy and regulations for XT require continuous engagement with the underlying public opinions. We learned that meaningful public engagement with emerging biomedical technologies involves sustained processes of familiarization, communication, and dialogue between science, society, and policy.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16536</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16536</link>
        <title><![CDATA[Beyond the gift: unveiling the impact of donor-recipient relationship on donors’ quality of life and mental health – results of a european bi-center study]]></title>
        <pubdate>2026-09-02T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Christina Papachristou</author><author>Natalia Papoulaki</author><author>Entela Kondi</author><author>Klemens Budde</author><author>Xavier Torres</author><author>Nina Babel</author><author>Ignacio Revuelta</author>
        <description><![CDATA[While living kidney donation is considered safe and beneficial, long-term psychosocial donor outcomes remain under-explored, particularly regarding donor-recipient relationships and caregiving dimensions. This study examined quality of life (QoL) and psychological outcomes among 713 living kidney donors from two major European transplant centers, assessing QoL, anxiety, depression and somatization alongside donor-recipient relationship types, caregiver role, caregiving burden and perceived responsibility for the recipient’s health. After adjusting for gender, age, center and time since donation, relationship type was not associated with physical wellbeing, but was linked to lower mental wellbeing in spouse donors compared to child-to parent and other genetically related donors. Caregiver role was linked to lower mental wellbeing and increased anxiety, caregiving burden with higher somatization, and perceived responsibility for recipient’s health with higher depression. Identified differences in mental health between centers likely reflect cultural and organisational characteristics, while differences in wellbeing linked to older age and time since donation are eventually understood within ageing processes. Conclusively, caregiving burden and perceived responsibility for the recipient’s health emerged as key predictors of psychological distress, while the effect of relationship type on wellbeing remains inconclusive. While most donors demonstrate good psychosocial outcomes, at-risk subgroups warrant appropriate attention prior and after donation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17659</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17659</link>
        <title><![CDATA[Correction: Blood pressure control after solid organ transplantation: opportunities for optimizing care]]></title>
        <pubdate>2026-09-01T00:00:00Z</pubdate>
        <category>Correction</category>
        <author>Transplant International Production Office </author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17404</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17404</link>
        <title><![CDATA[Dual-clamp technique facilitating end-to-side suture anastomosis in murine cervical heart transplantation]]></title>
        <pubdate>2026-09-01T00:00:00Z</pubdate>
        <category>Letter to the Editor</category>
        <author>Xia Huang</author><author>Xuechun Zhao</author><author>Zipei Wang</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16252</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16252</link>
        <title><![CDATA[The SystemCHANGE™ intervention improves immunosuppressive medication-taking habit: a secondary analysis of the MAGIC studies]]></title>
        <pubdate>2026-09-01T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Cynthia L. Russell Lippincott</author><author>Antoine Pironet</author><author>Yaprak Sarigol Ordin</author><author>Rebecca Bartlett Ellis</author><author>Buket Celik</author><author>Eda Ayten Kankaya</author><author>Mary Beth Stephens</author><author>Serkan Yildiz</author><author>Preethi Yerram</author><author>Wuraola Awopetu</author><author>Mark Wakefield</author><author>Elizabeth Henderson</author>
        <description><![CDATA[Habit impacts healthy behaviors. The SystemCHANGE™ intervention supports associating medication taking with existing habits or creating new habits to improve medication adherence. This secondary analysis of United States and Türkiye MAGIC study data examines differences in habit between SystemCHANGE™ and attention control groups, differences in habit between countries, and habit as a relationship mediator between the SystemCHANGE™ intervention and immunosuppressive medication adherence in adult kidney transplant recipients. The Medication Event Monitoring System measured medication adherence. Objective habit index was computed during screening, intervention, and maintenance. During the SystemCHANGE™ intervention, habit strength was higher than during the screening and maintenance periods in both groups (mean difference 0.042, 95% confidence interval (CI): 0.004 to 0.080, p = 0.030). Habit index was lower for US participants compared to Turkish participants (mean difference −0.195, 95% CI: −0.300 to −0.089, p < 0.001). Habit was a mediator of the SystemCHANGE™ intervention on medication adherence (indirect effect was 0.094, 95% CI: 0.080 to 0.114, p < 0.001). The SystemCHANGE™ intervention exerted an impact on habit in two different populations which then had a positive impact on medication adherence.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16498</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16498</link>
        <title><![CDATA[Foundations for consensus on establishing a unified definition of death: results of the European Society for Organ Transplantation Bucharest International Consensus Conference]]></title>
        <pubdate>2026-09-01T00:00:00Z</pubdate>
        <category>Consensus Report</category>
        <author>Francesco Procaccio</author><author>Alexandra Glazier</author><author>Beatriz Domínguez-Gil</author><author>Corinne Antoine</author><author>James Bernat</author><author>Helen Opdam</author><author>Mario Royo-Villanova</author><author>Gabriel C. Oniscu</author><author>Umberto Cillo</author><author>Dominique E. Martin</author>
        <description><![CDATA[As part of the ESOT International Consensus on Controlled Donation After Circulatory Determination of Death (cDCDD) Project, a dedicated working group addressed considerations relating to the determination of death in the context of cDCDD. Delphi methodology was used to explore international perspectives on the definition of death, and clinical and ethical standards for the determination of death in the setting of cDCDD. The results indicated consensus that establishing a “single unified definition of death worldwide” and specifically the “unifying brain-based concept of death” would be beneficial. There was consensus on the proposed definition of this concept and several principles relating to the determination of death in the context of cDCDD, such as the “dead donor rule.” However, limited agreement was reached on the more practical aspects of death determination. The results nevertheless provide a foundation for current policy and practice and should guide further efforts to establish minimum clinical standards for the determination of death in the context of cDCDD.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16292</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16292</link>
        <title><![CDATA[Pre-transplant whole blood transcriptomic profiling identifies mRNAs linked to cirrhosis-associated immune dysfunction as candidate predictors of clinical outcomes after liver transplantation: an exploratory study]]></title>
        <pubdate>2026-08-28T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Marie-Charlotte Delignette</author><author>Estelle Peronnet</author><author>Arnaud Riff</author><author>Teresa Antonini</author><author>Maxime Bodinier</author><author>Elisabeth Cerrato</author><author>Solène Pantel</author><author>Elsa Coz</author><author>Xavier Muller</author><author>Guillaume Rossignol</author><author>Jean-Yves Mabrut</author><author>Jérôme Dumortier</author><author>Céline Guichon</author><author>Alice Blet</author><author>Frederic Aubrun</author><author>Guillaume Monneret</author><author>Fanny Lebossé</author>
        <description><![CDATA[Cirrhosis-associated immune dysfunction (CAID) contributes to poor outcomes after liver transplantation (LT), but pre-transplant immune predictors remain insufficiently defined. We investigated whether pre-transplant whole blood transcriptomic profiling was associated with post-LT outcomes in this exploratory ancillary study of the prospective EDMONHG cohort. Transcriptomic analysis of 26 immune-related genes was performed on 97 LT recipients. PCA and volcano plots identified candidate biomarkers; associations with outcomes were assessed using ROC analyses and Kaplan-Meier estimates with cohort medians as thresholds. PC1 (43.5% of variance) decreased progressively from cACLD to ALF (p < 0.001) and was lower in post-LT infected patients (p = 0.044). Within the first month, 34 patients (35%) developed infections; 7 (7.2%) died within 1 year. Three genes met predefined exploratory criteria (q < 0.10, AUC > 0.65) for infections: GNLY and IL7R were downregulated and IL10 upregulated. Low GNLY or high IL10 expression was associated with reduced 30-day infection-free survival (p = 0.019 and p = 0.013). CIITA, IL10, CD177 and S100A9 showed associations with one-year survival, though results should be treated as exploratory given the limited number of events. Pre-transplant transcriptomics captures CAID severity and identifies candidate gene signatures associated with post-LT outcomes. These hypothesis-generating findings warrant validation in larger multicenter cohorts.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17566</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17566</link>
        <title><![CDATA[The bucharest international (ESOT) consensus on controlled donation after circulatory determination of death]]></title>
        <pubdate>2026-08-28T00:00:00Z</pubdate>
        <category>Special Issue Editorial</category>
        <author>Umberto Cillo</author><author>Gabriel C. Oniscu</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17461</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17461</link>
        <title><![CDATA[Correction: The European Board of transplant medicine: evolution, present role and future directions toward harmonised transplant medicine training in Europe]]></title>
        <pubdate>2026-08-28T00:00:00Z</pubdate>
        <category>Correction</category>
        <author>Nuria Montero</author><author>Miha Arnol</author><author>Susanne Beckebaum</author><author>Isabelle Binet</author><author>Vito Cicinnati</author><author>David Cucchiari</author><author>Caroline Den Hoed</author><author>Antoine Durrbach</author><author>Speranta Iacob</author><author>Smaragdi Marinaki</author><author>Anna Paola Mitterhofer</author><author>Anna Mrzljak</author><author>Adam Remport</author><author>Pablo Ruiz</author><author>Susana Sampaio</author><author>Francesca Tinti</author><author>Marios Prikis</author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17532</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.17532</link>
        <title><![CDATA[Correction: Nurturing a sustainable transplantation journey: the best of ESOT congress 2025]]></title>
        <pubdate>2026-08-28T00:00:00Z</pubdate>
        <category>Correction</category>
        <author>Transplant International Production Office </author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16769</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16769</link>
        <title><![CDATA[Alcohol-related liver disease and access to liver transplantation: where we stand and where we should go]]></title>
        <pubdate>2026-08-27T00:00:00Z</pubdate>
        <category>Point of View</category>
        <author>Inês Mega</author><author>Eloisa Franchi</author><author>Giacomo Germani</author><author>Hermien Hartog</author><author>Speranta Iacob</author><author>Phillipe Mathurin</author><author>Silvio Nadalin</author><author>Stephen Potts</author><author>Giuliano Testa</author><author>Luca Saverio Belli</author>
        <description><![CDATA[Alcohol-related liver disease (ArLD) is now a leading indication for liver transplantation worldwide, yet access to this life-saving therapy remains inequitable. Late diagnosis, persistent stigma, rigid abstinence requirements, and fragmented care pathways continue to disadvantage patients with ArLD relative to those with other liver diseases. Landmark studies have shown that early liver transplantation for severe alcohol-associated hepatitis confers a clear survival benefit when performed within rigorous selection protocols, with rates of return to drinking comparable to those achieved under the long-standing six-month abstinence rule, thereby challenging its clinical rationale. Concurrently, growing evidence supports the integration of addiction medicine and mental health expertise into transplant programs, recognizing alcohol use disorder as a chronic relapsing disease requiring sustained, multidisciplinary management. Despite this progress, substantial variability persists across centers in candidate evaluation, psychosocial assessment, and post-transplant addiction care. This Point of View examines the current landscape across six interconnected domains, epidemiology, timing of diagnosis, the dual nature of ArLD as a disease of mind and liver, stigma, access to transplantation, and multidisciplinary models of care, and proposes directions for harmonized, evidence-based, and equitable practice.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16834</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16834</link>
        <title><![CDATA[Kidney-alone transplantation in prior SLK candidates: a national registry analysis]]></title>
        <pubdate>2026-08-27T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Beat Moeckli</author><author>Kevin B. Harris</author><author>Byron Smith</author><author>David Pereyra</author><author>Xiomara Benavides</author><author>Jody Olson</author><author>Alexander R. Cortez</author><author>Timucin Taner</author><author>Julie K. Heimbach</author><author>Douglas A. Simonetto</author><author>Samy M. Riad</author>
        <description><![CDATA[Outcomes of kidney-alone transplantation (KAT) in former simultaneous liver-kidney (SLK) transplant candidates after liver waitlist delisting are not well defined. Using Scientific Registry of Transplant Recipients (SRTR) data, we identified adult recipients who underwent KAT between 2005 and 2025 after prior SLK listing (RLD-KAT), which was matched 1:5 to primary KAT recipients without liver disease by age, transplant year, and diabetes status. Patient and graft survival were evaluated using the Kaplan-Meier method and multivariable Cox proportional hazards models. We identified 163 RLD-KAT recipients matched to 815 controls. Unadjusted Kaplan-Meier analyses demonstrated lower patient survival in RLD-KAT (p = 0.020), whereas death-censored and overall graft survival were similar (p > 0.05). In multivariable models, death-censored graft survival (HR 0.89; 95% CI 0.51–1.53), overall graft survival (HR 1.00; 95% CI 0.73–1.36), and patient survival (HR 1.07; 95% CI 0.76–1.5) did not differ significantly. Six RLD-KAT recipients (3.7%) subsequently underwent liver transplantation. Kidney-alone transplantation in prior SLK candidates was associated with acceptable patient and graft outcomes and a low incidence of subsequent liver transplantation.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16004</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16004</link>
        <title><![CDATA[Abdominal normothermic regional perfusion is associated with improved graft survival in liver transplantation from circulatory death donors]]></title>
        <pubdate>2026-08-26T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Giulia Magini</author><author>Hannah Wozniak</author><author>Antonia Schafer</author><author>Beat Moeckli</author><author>Vanessa Banz</author><author>Julien Vionnet</author><author>Ansgar Deibel</author><author>Jose Oberholzer</author><author>Pascale Tinguely</author><author>Nicolas Goossens</author><author>Andrea Peloso</author><author>Mirjam Korner</author><author>Franz Immer</author><author>Riccardo De Carlis</author><author>Christian Toso</author><author>Benjamin Assouline</author><author>Karim Bendjelid</author><author>Philippe Compagnon</author><author>Raphael Giraud</author>
        <description><![CDATA[Advanced preservation strategies are increasingly used in liver transplantation following donation after circulatory death (DCD). This nationwide observational study evaluated the association between abdominal normothermic regional perfusion (A-NRP) and 1-year graft survival in a Swiss cohort of 254 DCD liver transplants performed between 2017 and 2023. Recovery strategies compared included A-NRP and super-rapid recovery (SRR), both predominantly followed by end-ischemic hypothermic oxygenated perfusion (HOPE). Primary endpoint was 1-year graft loss; secondary endpoints included 1-year patient mortality, primary non-function, non-anastomotic strictures (NAS), biliary and vascular complications and need for re-transplantation. Overall, 53 grafts were retrieved using A-NRP (71% followed by HOPE) and 201 using SRR (90% followed by HOPE). Compared with SRR, A-NRP grafts demonstrated lower rates of graft loss (5.7% vs. 24.6%), 1-year mortality (1.9% vs. 13.3%), NAS (5.7% vs. 20.5%), other biliary complications (1.9% vs. 12.6%) and re-transplantation (3.8% vs. 12.8%). In multivariable Cox regression analysis, A-NRP was associated with lower risk of 1-year graft loss and patient mortality after adjustment for UK DCD risk category and HOPE use. These findings suggest that A-NRP is associated with improved outcomes. Further studies are needed to define the role of ex-situ perfusion after A-NRP in optimizing results.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16845</guid>
        <link>https://www.frontierspartnerships.org/articles/10.3389/ti.2026.16845</link>
        <title><![CDATA[Hypoimmune platforms: from rejection to immune evasion and regulatory implications]]></title>
        <pubdate>2026-08-25T00:00:00Z</pubdate>
        <category>Review</category>
        <author>Francesco Campo</author><author>Maria Irene Bellini</author><author>Hanne Scholz</author><author>Lorenzo Piemonti</author><author>Antonio Citro</author>
        <description><![CDATA[The growing gap between organ demand and clinical availability has renewed interest in immune-evasive graft strategies, yet rejection and lifelong immunosuppression remain major barriers to durable success. Advances in genome editing enable immune-evasive cell platforms designed to avoid immune recognition while replacing missing function in allogeneic settings. This review summarizes current strategies for engineering immune-evasive grafts that simultaneously suppress adaptive and innate immune responses. We discuss how coordinated modulation of antigen presentation and immune checkpoint pathways can protect transplanted allogeneic cells and tissues from T, NK, and macrophage-mediated rejection. We also present the emerging concept of integrating hypoimmune engineering with genetically modified porcine donors, where extensive genome editing has reduced, but not eliminated, xenogeneic immune barriers. Combining donor genome modification with immune-evasive graft design represents a promising conceptual advance toward xenograft survival, though whether full elimination of systemic immunosuppression is achievable remains to be established clinically. We further examine how the regulatory landscape for these products is evolving across major jurisdictions, and how differences in approval pathways, manufacturing standards, and long-term surveillance requirements shape the path to clinical translation. Finally, we outline the safety considerations and remaining limitations in immune evasion that must be addressed to enable clinical implementation.]]></description>
      </item>
      </channel>
    </rss>